Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.
Anti-myelin-associated glycoprotein (MAG) neuropathy is a primary demyelinating sensorimotor polyneuropathy that can be very debilitating and is known to be resistant to treatment. There are only a few conflicting reports on the effect of Rituximab in anti-MAG neuropathy. We present three patients who improved remarkably with Rituximab infusions. Until the safety and efficacy of this drug are determined in larger controlled studies, use of Rituximab should be limited to patients with significant neurologic deficits.
Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey , Newark, NJ , USA .
Nizar
N
Souayah
Raje
R
Noopur
Peter Siao
PS
Tick-Chong
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; C115082:MAG protein, human; D018992:Myelin-Associated Glycoprotein; D000069283:Rituximab